No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends hydroxyzine for chronic insomnia, and zero randomized trials have tested it in diagnosed chronic insomnia disorder or against first-line CBT-I (very low evidence certainty; 5 small studies totaling 207 adults, Burgazli 2023). While H1-receptor sedation often fades within 3 to 4 days (Richardson 2002), hydroxyzine's 20-hour half-life causes next-day driving impairment equal to a 0.08% blood alcohol concentration on Day 1 and 0.05% on Day 8 (Conen 2011; crash responsibility OR 1.67 to 2.60 in Orriols 2017). It also carries FDA and EMA warnings for QTc prolongation and torsades de pointes and a strong AGS Beers Criteria (2023) recommendation to avoid in adults 65 and older due to anticholinergic delirium, fall, and cumulative dementia risk.
TL;DR: Hydroxyzine (Atarax, Vistaril, 10 to 50 mg off-label at bedtime) is an old allergy and anxiety drug often prescribed for sleep because it is not a controlled substance. Clinical trials show a sharp mismatch between its fading sleep benefit and its lingering harms:
- Zero guideline endorsement (AASM, ACP, VA/DoD) and very low evidence certainty (Burgazli 2023): No major guideline recommends hydroxyzine for insomnia. Across the medical literature, only 5 small studies (207 patients total) have tested hydroxyzine for sleep. Zero RCTs have enrolled adults with chronic insomnia disorder or compared it with CBT-I. By contrast, multicomponent CBT-I holds a strong first-line recommendation (SOL -19 min, WASO -26 min, lasting at 12 months).
- The H1 tolerance vs. next-day driving trap (Richardson 2002; Conen 2011; Orriols 2017): Histamine H1 sedation fades fast (3 to 4 days in Richardson 2002), yet hydroxyzine has a ~20-hour half-life. In an on-road driving RCT (Conen et al., 2011), 50 mg of hydroxyzine caused lane weaving equal to a 0.08% blood alcohol level on Day 1 and still equal to 0.05% on Day 8. In a study of 142,771 drivers (Orriols 2017), hydroxyzine raised at-fault crash odds by 67% to 160% (OR 1.67 to 2.60).
- Heart rhythm (QTc / torsades) and Beers Criteria anticholinergic harms (EMA 2015; FDA 2025/2026; Beers 2023): Both the FDA and European regulators (EMA) warn that hydroxyzine stretches the QTc interval and can trigger torsades de pointes. It is contraindicated in heart disease or with QT-stretching drugs (citalopram, escitalopram, fluoroquinolones, macrolides, or ondansetron). The 2023 AGS Beers Criteria strongly advise avoiding hydroxyzine in adults >= 65 due to confusion, falls, and dementia risk (Gray 2015; Coupland 2019).
A 43-year-old nurse from Northern Liberties came into my Fishtown clinic after taking 50 mg of hydroxyzine at 11:00 PM every night for six months alongside 20 mg of escitalopram (Lexapro). Her bedtime drowsiness had worn off after the first week. She still lay awake past 1:00 AM at night, yet felt so heavy-lidded at 7:00 AM that she drifted onto the I-95 rumble strip driving to her hospital shift. We checked a baseline ECG (since hydroxyzine and escitalopram both stretch the QTc interval), stopped the nightly hydroxyzine, and guided her through a four-week CBT-I sleep consolidation plan. Her morning lane-drifting vanished in two days, and her sleep latency dropped below 20 minutes by week three.
What do sleep guidelines say about hydroxyzine vs. CBT-I?
No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends hydroxyzine for chronic or short-term insomnia. Every guideline recommends multicomponent CBT-I as strong first-line care (moderate certainty), while warning against sedating antihistamines (very low to low certainty).12345
| Guideline Body | Multicomponent CBT-I Status | Hydroxyzine Status | Closest Antihistamine Ruling (Diphenhydramine) |
|---|---|---|---|
| AASM Pharmacologic (Sateia et al., JCSM 2017) & Behavioral (Edinger et al., JCSM 2021) | STRONG recommendation for CBT-I first-line (moderate certainty, 49 RCTs).2 | Not reviewed; no recommendation (lack of insomnia RCT data).1 | WEAK recommendation AGAINST diphenhydramine (50 mg) for sleep onset or stay-asleep care (low certainty; no meaningful gain).1 |
| American College of Physicians (Qaseem et al., Ann Intern Med 2016) | STRONG recommendation for CBT-I as first treatment (moderate certainty).3 | Not named; antihistamines noted only as off-label.3 | First-generation antihistamines and trazodone listed as lacking sufficient study.3 |
| VA/DoD Insomnia & OSA Guidelines (Mysliwiec 2020; Sharafkhaneh 2025) | STRONG recommendation for CBT-I (moderate certainty) over drugs first-line.45 | No studies met inclusion rules for antihistamines.45 | WEAK recommendation AGAINST antihistamines (very low confidence), citing tolerance within 3 to 4 days and anticholinergic harm.45 |
Why the guideline silence matters: No society found qualifying chronic-insomnia RCTs of hydroxyzine to grade. Applying standard GRADE rules (downgrading for wrong study groups, tiny samples, and bias) places the certainty of evidence for hydroxyzine in insomnia at very low.156
What do human clinical trials show (Hydroxyzine vs. Placebo and CBT-I)?
A 2023 systematic review (Burgazli et al., Hum Psychopharmacol 2023) found only 5 small studies (4 RCTs and 1 open-label study; 207 adults total) testing hydroxyzine (25 to 100 mg) for sleep. Zero trials enrolled patients with chronic insomnia disorder, zero lasted past a few weeks, and zero compared hydroxyzine with CBT-I.67
| Study / Population | Design & Sample (n) | Dose & Duration | Sleep Outcome vs. Placebo or Control | Documented Harms & Limits |
|---|---|---|---|---|
| Healthy Volunteers (Alford et al., Hum Psychopharmacol 2004) | Double-blind crossover RCT (n = 12) | Single night: 25 mg or 50 mg vs placebo | Cut sleep-onset latency (SOL) from 16.6 min to 7.2 min (-9.4 min; -57%); total sleep (TST) +24.5 min at 25 mg only; zero change in deep sleep.67 | Next-day objective drowsiness in women; tested healthy sleepers (16.6 min baseline SOL), not insomnia patients.7 |
| Cirrhosis + Minimal Hepatic Encephalopathy (Spahr et al., Am J Gastroenterol 2007) | Double-blind parallel RCT (n = 35) | 25 mg at bedtime for 10 days | Subjective sleep improved in 40% vs 0%; >= 30% actigraphy efficiency gain in 65% vs 25% (p < 0.04).8 | Caused overt liver encephalopathy in 1 patient (hydroxyzine is cleared by the liver); 10-day trial only.8 |
| Dysthymia on SSRIs (Kotan et al., 2015, in Burgazli 2023) | Randomized trial | Bedtime hydroxyzine vs placebo | Worsened sleep: falling asleep took +14.7 minutes longer and total sleep dropped by ~80 minutes vs placebo.6 | Shows hydroxyzine can worsen sleep in adults taking SSRI antidepressants.6 |
| PTSD Nightmares (Ahmadpanah et al., 2014, in Burgazli 2023) | Randomized trial (8 weeks) | 100 mg at bedtime vs prazosin vs placebo | Improved PSQI score and cut nightmares vs placebo (less helpful than prazosin).6 | Trauma cohort; 100 mg hits the maximum adult QTc safety ceiling.6 |
| Comparator Benchmark: Multicomponent CBT-I (Trauer et al., Ann Intern Med 2015; Gao et al., 2022; Morin & Buysse, NEJM 2024) | 20 RCT meta-analysis (n = 1,162) & 61 RCT network (n = 11,571) | 4 to 8 sessions (in-person or digital) | SOL -19.0 min (95% CI -14.1 to -23.9), WASO -26.0 min (-15.5 to -36.5), sleep efficiency +9.9%; 60% to 70% response and 40% to 45% remission at 12 months.91011 | Across 23 head-to-head RCTs vs sleep pills (Zhang 2022; Perlis Lancet 2022), only CBT-I keeps working after treatment ends.1213 |
Why does hydroxyzine stop helping you sleep within days while next-day driving risk stays high?
First-generation H1 sedation tolerance builds within 3 to 4 days (Richardson et al., J Clin Psychopharmacol 2002), and hydroxyzine's FDA label notes that subjective drowsiness often fades after a few days. However, its 20.0 +/- 4.1 hour adult half-life (29.3 +/- 10.1 hours in older adults, Simons 1984/1989) keeps increasing next-day somnolence (Staevska 2014) and highway lane weaving (Conen 2011; Orriols 2017).141516173435
- Rapid H1 sedation tolerance vs. nighttime sleep (Richardson 2002; FDA Label; Staevska 2014): In the classic H1 tolerance study (Richardson et al., 2002, n = 15 taking diphenhydramine 50 mg twice daily), daytime sleepiness on nap tests and self-report matched placebo by Day 4.14 For hydroxyzine, the FDA label notes that subjective drowsiness may fade after a few days.2122 In a crossover trial of bedtime dosing (Staevska et al., Br J Dermatol 2014, n = 24), hydroxyzine 50 mg at night increased next-day sleepiness without improving sleep over a nonsedating antihistamine.35
- Long half-life and highway driving risk (Simons 1984/1989; Goetz 1989; Conen et al., J Psychopharmacol 2011): Feeling less sleepy does not mean safe driving. Elimination studies (Simons et al., JACI 1984 & Clin Pharmacol Ther 1989) measured hydroxyzine's half-life at 20.0 +/- 4.1 hours in young adults and 29.3 +/- 10.1 hours in older adults.34 In a crossover trial (Goetz et al., JACI 1989, n = 16), twice-daily hydroxyzine (25 mg) slowed reaction times across all 5 days.15 In a highway-driving RCT (Conen et al., J Psychopharmacol 2011), 50 mg of hydroxyzine increased lane weaving (SDLP) by +4.7 cm on Day 1 (matching a 0.08% blood alcohol level) and by +2.2 cm on Day 8 (matching a 0.05% blood alcohol level) - even when drivers felt alert.16
- Traffic crash risk (Orriols et al., Accid Anal Prev 2017; Bierly & D'Orazio, J Anal Toxicol 2025): In a French study of 142,771 injury crashes (Orriols et al., 2017), filling a hydroxyzine prescription raised at-fault crash odds by 67% (OR 1.67, 95% CI 1.22 to 2.30), rising to OR 2.60 (160% higher odds) at highest exposure.17 By 2023, hydroxyzine passed diphenhydramine as the top antihistamine found in US impaired-driving blood tests (Bierly & D'Orazio, 2025).20
What are the heart rhythm (QTc), anticholinergic (Beers Criteria), and skin risks?
Hydroxyzine carries FDA and EMA warnings for QTc prolongation and torsades de pointes, a strong 2023 AGS Beers Criteria rule to avoid in adults 65 and older due to delirium and falls, and an FDA warning for severe pustular skin rash (AGEP).18212223
1. QTc Prolongation and Torsades de Pointes (FDA Label 2025/2026; EMA PRAC 2015)
Hydroxyzine blocks heart hERG potassium channels at higher blood levels, slowing heart recovery:
- Heart safety rules (EMA 2015; Morales 2021; Morrow 2022; Ali FAERS 2021): After reports of QT prolongation and torsades de pointes (Ali et al., Expert Opin Drug Saf 2021), European (EMA PRAC 2015), UK, and Canadian regulators barred hydroxyzine in anyone with known QT prolongation, heart disease, family history of sudden cardiac death, slow heart rate (bradycardia), or low potassium/magnesium.2122232425 Regulators also capped total daily doses at 100 mg/day in adults and 50 mg/day in older adults.2326 New starts in heart patients dropped right away (-46.2 per 100,000 in Scotland and -36.5 in England, Morales et al., 2021).23
- Drug interactions that raise QTc risk (FDA Label): Do not combine hydroxyzine with other QT-stretching drugs. That list includes heart-rhythm drugs (quinidine, procainamide, amiodarone, sotalol), citalopram or escitalopram, antipsychotics (haloperidol, quetiapine, ziprasidone), fluoroquinolones (ciprofloxacin, moxifloxacin), macrolides (azithromycin, erythromycin), ondansetron, and methadone.2122
2. Anticholinergic Burden & Cumulative Dementia Cohorts (AGS Beers Criteria 2023; Gray 2015; Coupland 2019)
In lab assays (Orzechowski et al., Eur J Pharmacol 2005), hydroxyzine has less antimuscarinic activity than diphenhydramine, yet it still causes dry mouth, urinary retention, and confusion in older adults:1836
- 2023 AGS Beers Criteria (Strong Avoid in Age >= 65): The American Geriatrics Society lists hydroxyzine alongside diphenhydramine and doxylamine as a first-generation antihistamine to avoid in older adults. It also gives a strong rule against combining two or more anticholinergic drugs.18 Short-term harms include dry mouth, constipation, blurry vision, trouble urinating, delirium, and falls.18
- Long-term dementia cohorts (Gray et al., JAMA Intern Med 2015; Richardson et al., BMJ 2018; Coupland et al., JAMA Intern Med 2019): In Gray et al. (2015) (n = 3,434), > 1,095 daily doses of strong anticholinergics over 10 years was linked with a 54% higher dementia risk (HR 1.54; Alzheimer's HR 1.63).27 In two UK case-control studies (Richardson et al., BMJ 2018, 40,770 cases; Coupland et al., JAMA Intern Med 2019, 58,769 cases), strong anticholinergic exposure raised dementia odds (OR 1.49), driven by anticholinergic antidepressants (OR 1.29), bladder drugs, and Parkinson drugs (OR 1.14 non-significant for prescribed antihistamines).2829 Observational cohorts show association instead of drug-specific causation. Still, skipping nightly anticholinergic sleep pills is an easy win when safer options exist.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
3. Rare Pustular Skin Rash (AGEP) & Cetirizine Cross-Sensitivity (FDA Label)
Hydroxyzine breaks down in the liver into cetirizine (Zyrtec). The FDA label warns that hydroxyzine can rarely cause a severe pustular rash (AGEP). Anyone with a prior rash to hydroxyzine, cetirizine, or levocetirizine should avoid all three drugs.2122
How does hydroxyzine compare with better sleep options?
- Against Multicomponent CBT-I (First-Line for Chronic Insomnia): CBT-I wins on every measure. Across 49+ RCTs (Edinger 2021; Trauer 2015; Scott JAMA Intern Med 2025; Bai 2024; Xu 2024), CBT-I cuts time to fall asleep by 19 minutes and night waking by 26 minutes.29303132 It keeps 40% to 45% of patients in remission a year later with zero QTc, driving, or anticholinergic cost.
- Against Low-Dose Doxepin (3 to 6 mg) (When an H1 Blocker Is Wanted for Sleep Maintenance): At 3 to 6 mg, doxepin selectively blocks H1 receptors with minimal anticholinergic effect.1 It holds FDA approval for staying asleep and carries an AASM 2017 recommendation.1
- Against Dual Orexin Blockers (Lemborexant, Daridorexant): Orexin blockers quiet wake signals without anticholinergic load, QTc risk, or sleep apnea worsening (Kishi et al., 2026).33
Guidance from the Clinic
Actionable Steps
How to audit and replace nightly hydroxyzine safely:
- Check the Hard Stop List (QTc, Heart Disease, Age >= 65, Liver Disease): Skip hydroxyzine if you have a long QTc, heart disease (EMA 2015), cirrhosis (Spahr 2007), narrow-angle glaucoma, urinary retention, are 65 or older (Beers 2023), or take QT-stretching drugs (citalopram, escitalopram, ondansetron, fluoroquinolones, macrolides).
- Keep Any Situational Use to <= 3 to 7 Nights at 10 to 25 mg: H1 sedation tolerance builds within 3 to 4 days (Richardson 2002), and 50 mg causes next-day lane weaving equal to 0.05% to 0.08% blood alcohol (Conen 2011). Avoid raising the dose when it stops working.
- Leave at Least 10 to 12 Hours Before Driving: With a ~20-hour half-life, taking hydroxyzine at midnight leaves high drug levels in your bloodstream during your morning drive (Orriols 2017 crash OR 1.67 to 2.60).
- Screen for Obstructive Sleep Apnea Before Using Any Sedative: Morning grogginess and unrefreshing sleep often point to untreated sleep apnea instead of primary insomnia.
- Move Chronic Insomnia to CBT-I: If you have taken hydroxyzine or diphenhydramine for months, start an intake with Dr. Ash so we can step down the antihistamine and build a lasting CBT-I plan.
Key Takeaways
- No major guideline (AASM 2017/2021, ACP 2016, VA/DoD 2019/2025) recommends hydroxyzine for chronic insomnia, and zero RCTs have tested it in chronic insomnia disorder (very low certainty across 5 small studies / n = 207, Burgazli 2023).1356
- Multicomponent CBT-I is the strong first-line recommendation across all guidelines (SOL -19 min, WASO -26 min, 60% to 70% response lasting at 12 months, Trauer 2015; Edinger 2021).2911
- Sedation fades within 3 to 4 days (Richardson 2002), while next-day driving risk stays high (~20-hour half-life): 50 mg caused lane weaving equal to 0.08% BAC on Day 1 and 0.05% BAC on Day 8 (Conen 2011), with 1.67x to 2.60x higher at-fault crash odds (Orriols 2017).141617
- Screen out QTc risk factors and older age (>= 65): Hydroxyzine carries FDA and EMA warnings for QTc prolongation / torsades de pointes (Morales 2021; Ali 2021) and a 2023 AGS Beers Criteria strong recommendation to avoid due to delirium, falls, and dementia risk.18212327
Related at Fishtown Medicine
- CBT-I for insomnia
- Sleeping pills comparison guide
- Gabapentin for sleep
- Doxepin for sleep
- Doxepin (3-6 mg) vs. hydroxyzine (25-50 mg) for sleep
- Trazodone for sleep
- Is it insomnia or sleep apnea?
- Insomnia
Scientific References
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(2):307-349. PMC
- Edinger JD, Arnedt JT, Bertisch SM, et al. "Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2021;17(2):255-262. PMC
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine. 2016;165(2):125-133. DOI
- Mysliwiec V, Martin JL, Ulmer CS, et al. "The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines." Annals of Internal Medicine. 2020;172(5):325-336. PubMed
- Sharafkhaneh A, Thomas A, Ulmer C, et al. "VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (Insomnia/OSA)." Department of Veterans Affairs & Department of Defense. 2025. Guideline PDF
- Burgazli CR, Rana KB, Brown JN, Tillman F. "Efficacy and safety of hydroxyzine for sleep in adults: Systematic review." Human Psychopharmacology. 2023;38(2):e2864. DOI
- Alford C, Rombaut N, Jones J, Foley S, Idzikowski C, Hindmarch I. "Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: A C-EEG study." Human Psychopharmacology: Clinical and Experimental. 1992;7(1):25-35. DOI
- Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. "Histamine H1 Blocker Hydroxyzine Improves Sleep in Patients With Cirrhosis and Minimal Hepatic Encephalopathy: A Randomized Controlled Pilot Trial." The American Journal of Gastroenterology. 2007;102(4):744-753. PubMed
- Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. "Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-Analysis." Annals of Internal Medicine. 2015;163(3):191-204. PubMed
- Gao Y, Ge L, Liu M, et al. "Comparative Efficacy and Acceptability of Cognitive Behavioral Therapy Delivery Formats for Insomnia in Adults: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;64:101648. PubMed
- Morin CM, Buysse DJ. "Management of Insomnia." The New England Journal of Medicine. 2024;391(3):247-258. DOI
- Zhang Y, Ren R, Yang L, et al. "Comparative Efficacy and Acceptability of Psychotherapies, Pharmacotherapies, and Their Combination for the Treatment of Adult Insomnia: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;65:101687. PubMed
- Perlis ML, Posner D, Riemann D, Bastien CH, Teichtenberg L, Thase M. "Insomnia." The Lancet. 2022;400(10357):1047-1060. PubMed
- Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. "Tolerance to Daytime Sedative Effects of H1 Antihistamines." Journal of Clinical Psychopharmacology. 2002;22(5):511-515. PubMed
- Goetz DW, Jacobson JM, Murnane JE, et al. "Prolongation of Simple and Choice Reaction Times in a Double-Blind Comparison of Twice-Daily Hydroxyzine Versus Terfenadine." The Journal of Allergy and Clinical Immunology. 1989;84(3):316-322. PubMed
- Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. "Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers." Journal of Psychopharmacology. 2011;25(11):1517-1523. DOI
- Orriols L, Luxcey A, Contrand B, et al. "Road Traffic Crash Risk Associated With Prescription of Hydroxyzine and Other Sedating H1-Antihistamines: A Responsibility and Case-Crossover Study." Accident Analysis & Prevention. 2017;106:115-121. PubMed
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2023;71(7):2052-2081. DOI
- Simons FE. "Advances in H1-Antihistamines." The New England Journal of Medicine. 2004;351(21):2203-2217. DOI
- Bierly JJ, D'Orazio AL. "Hydroxyzine in Impaired Driving Investigations." Journal of Analytical Toxicology. 2025. PubMed
- Food and Drug Administration. "Hydroxyzine Hydrochloride Prescribing Information." Updated August 2025. DailyMed
- Food and Drug Administration. "Hydroxyzine Hydrochloride Tablets Prescribing Information." Updated June 2026. DailyMed
- Morales DR, Macfarlane T, MacDonald TM, et al. "Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis." Pharmacoepidemiology and Drug Safety. 2021;30(4):477-485. DOI
- Morrow RL, Mintzes B, Souverein PC, et al. "Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study." Drug Safety. 2022;45(6):623-638. DOI
- Ali Z, Ismail M, Khan F, Sajid H. "Association of H1-Antihistamines With Torsade De Pointes: A Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System." Expert Opinion on Drug Safety. 2021;20(1):101-107. PubMed
- Chen A, Metzger E, Lee S, Osser D. "A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient." Journal of Geriatric Psychiatry and Neurology. 2025;38(2):83-97. DOI
- Gray SL, Anderson ML, Dublin S, et al. "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study." JAMA Internal Medicine. 2015;175(3):401-407. PubMed
- Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. "Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study." JAMA Internal Medicine. 2019;179(8):1084-1093. PubMed
- Richardson K, Fox C, Maidment I, et al. "Anticholinergic drugs and risk of dementia: case-control study." BMJ. 2018;361:k1315. PubMed
- Scott AJ, Correa AB, Bisby MA, et al. "Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis." JAMA Internal Medicine. 2025. DOI
- Bai N, Cao J, Zhang H, Liu X, Yin M. "Digital cognitive behavioural therapy for patients with insomnia and depression: A systematic review and meta-analysis." Journal of Psychiatric and Mental Health Nursing. 2024;31(4):552-566. DOI
- Xu D, Li Z, Leitner U, et al. "Efficacy of Remote Cognitive Behavioural Therapy for Insomnia in Improving Health Status of Patients with Insomnia Symptoms: A Meta-analysis." Cognitive Therapy and Research. 2024;48:369-388. DOI
- Kishi T, Ikuta T, Sakuma K, et al. "Comparative Effects of Hypnotic Agents on Sleep Architecture and Respiratory Outcomes in Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis." Psychiatry and Clinical Neurosciences. 2026. PubMed
- Simons KJ, Watson WT, Chen XY, Simons FE. "Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly." Clinical Pharmacology and Therapeutics. 1989;45(1):9-14. PubMed
- Staevska M, Gugutkova M, Lazarova C, et al. "Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial." The British Journal of Dermatology. 2014;171(1):148-154. PubMed
- Orzechowski RF, Currie DS, Valancius CA. "Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models." European Journal of Pharmacology. 2005;506(3):257-264. PubMed
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.


